Acadian Asset Management
ECYT

Acadian Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Acadian Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-93,771
Closed -$376K – 1570
2015
Q4 		$376K Buy
+93,771
New +$432K ﹤0.01% 855
2013
Q3 		– Sell
-35,208
Closed -$462K – 1075
2013
Q2 		$462K Buy
+35,208
New +$475K ﹤0.01% 605

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management's ECYT Position: Q1 2016 in Review

Acadian Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2016, closing a stake of 93,771 shares — an estimated $376K sold.

Acadian Asset Management first reported a position in ECYT in Q2 2013 and held it in 2 quarters. The position peaked at $462K in Q2 2013. 97 funds tracked by Wall St. Rank hold ECYT as of Q1 2016.

  • Acadian Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Acadian Asset Management sold 93,771 Endocyte, Inc. Common Stock shares in Q1 2016, an estimated $376K.
  • Acadian Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Acadian Asset Management's Endocyte, Inc. Common Stock position peaked at $462K in Q2 2013.
  • 97 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2016.

Based on Acadian Asset Management's 13F filing for Q1 2016, filed 14 Apr 2016.